Abstract 1571
Background
Papillary carcinoma is the most common type of thyroid cancer and if it is not treated early, it can spread throughout the body. Therefore, the first line of treatment for papillary thyroid cancer is the surgery by removing part of or the entire thyroid. Our study aims to establish the most effective surgical procedure (total thyroidectomy or partial thyroidectomy) to achieve better survival for stage I and II papillary carcinoma and evaluate the effect of the ethnicity, sex and age on patients' survival undergoing these surgical techniques.
Methods
We extracted the data from the Surveillance, Epidemiology, and End Results (SEER) 18 registries. We retrieved data of 3691 patients diagnosed with papillary thyroid cancer in 2010. We evaluated the 5-year overall survival of patients using the log-rank test. Patients were grouped into two groups. The first one underwent thyroid lobectomy (242) and the second underwent total thyroidectomy (3449). Patients were further grouped according to ethnicity (white, black, American or Asian), sex (female or male) and age group.
Results
We found that total thyroidectomy was associated with better 5-year overall survival rates in patients with early stage papillary carcinoma, compared to lobectomy (98.1% and 96.5%, respectively, P = 0.021). Moreover, total thyroidectomy showed better survival rates in females than males (98.6% and 95.7%, respectively, p = 0.000) and in young patients aged between 20-39 years (99.8%, p = 0.000). Meanwhile, surgical techniques were not significantly associated with patients’ ethnicity.
Conclusions
Total thyroidectomy was superior to lobectomy in early stages papillary thyroid carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sara Ahmed.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3773 - Impact of centralisation of national cancer services on patient outcomes for hepatobiliary cancers in Ireland 2000 – 2016
Presenter: David O Reilly
Session: Poster Display session 2
Resources:
Abstract
3180 - Genomic analysis of hepatobiliary lithiasis associated cholangiocarcinoma revealed a distinct subtype feature.
Presenter: Lunda Gu
Session: Poster Display session 2
Resources:
Abstract
4891 - Comparison of the impact of stereotactic body radiation therapy vs. radiofrequency ablation on liver function in patients with single hepatocellular carcinoma: A propensity score matching analysis
Presenter: Masayuki Ueno
Session: Poster Display session 2
Resources:
Abstract
3203 - Exploratory analysis based on tumor location and early metabolic tumor response of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine/platinum-based chemotherapy for advanced and metastatic biliary tract tumors.
Presenter: Anne Demols
Session: Poster Display session 2
Resources:
Abstract
1602 - Predictive Value of Neutrophil-Lymphocyte Ratio (NLR) And Platelet-Lymphocyte Ratio (PLR) In Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab (N)
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2848 - Preliminary Safety and Pharmacokinetics of a New Lysosomotropic Oral Agent, GNS561, in a First-in-Human Study in Advanced Primary Liver Cancer Patients
Presenter: Ahmad Awada
Session: Poster Display session 2
Resources:
Abstract
1396 - A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1139 - Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study
Presenter: Andrea Casadei-gardini
Session: Poster Display session 2
Resources:
Abstract
4688 - Prognostic and predictive factors from the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Tim Meyer
Session: Poster Display session 2
Resources:
Abstract
1492 - A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.
Presenter: David Pinato
Session: Poster Display session 2
Resources:
Abstract